140 related articles for article (PubMed ID: 19137749)
1. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
2. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
3. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
4. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
5. Constitutional law--substantive due process--en banc D.C. Circuit rejects fundamental right to experimental medications.--Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach, 495 F.3d 695 (D.C. Cir. 2007)(en banc), cert. denied, 128 S. Ct. 1069 (2008).
Harv Law Rev; 2008 Apr; 121(6):1685-92. PubMed ID: 18524069
[No Abstract] [Full Text] [Related]
6. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
7. The terminally ill, access to investigational drugs, and FDA rules.
Blake V
Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785
[No Abstract] [Full Text] [Related]
8. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
9. Landmark approval for Dendreon's cancer vaccine.
DeFrancesco L
Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
[No Abstract] [Full Text] [Related]
10. A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach.
Jacobson PD; Parmet WE
JAMA; 2007 Jan; 297(2):205-8. PubMed ID: 17213404
[No Abstract] [Full Text] [Related]
11. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
Baghdadi R
Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
[No Abstract] [Full Text] [Related]
12. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
13. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
14. Investigational drugs and the constitution.
Dresser R
Hastings Cent Rep; 2006; 36(6):9-10. PubMed ID: 17278864
[No Abstract] [Full Text] [Related]
15. Cancer vaccine approval could open floodgates.
Nat Med; 2010 Jun; 16(6):615. PubMed ID: 20526296
[No Abstract] [Full Text] [Related]
16. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
18. Should terminally ill patients have access to phase I drugs?
Bristol N
Lancet; 2007 Mar; 369(9564):815-6. PubMed ID: 17366691
[No Abstract] [Full Text] [Related]
19. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
Joffe S; Lynch HF
N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
[No Abstract] [Full Text] [Related]
20. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
